Gene One Life Science

Gene One Life Science EBIT Margin

The EBIT Margin (Operating Margin) of Gene One Life Science (011000.KS) as of Oct 26, 2026 is -195.55 %. In the previous year, EBIT Margin (Operating Margin) was -130.45 % — a change of 49.90% (lower).

EBIT Margin

-195.55 %

YoY

49.90%

Last updated:

EBIT Margin (Operating Margin) of Gene One Life Science is 2025 -195.55 % . EBIT Margin (Operating Margin) of Gene One Life Science was 2024 -130.45 % . It decreases by 49.90% lower compared to the previous year.

For Gene One Life Science, the operating (EBIT) margin of -195.5% is down versus -71.1% a few years ago.

The Gene One Life Science EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-30.16 KRW
Jan 1, 2019
-19.90 KRW
Jan 1, 2020
-44.48 KRW
Jan 1, 2021
-71.08 KRW
Jan 1, 2022
-82.27 KRW
Jan 1, 2023
-190.22 KRW
Jan 1, 2024
-130.45 KRW
Jan 1, 2025
-195.55 KRW
The Gene One Life Science EBIT Margin history
YEAREBIT MarginYoY
-195.55 %+49.90%
-130.45 %-31.42%
-190.22 %+131.22%
-82.27 %+15.75%
-71.08 %+59.80%
-44.48 %+123.45%
-19.90 %-34.01%
-30.16 %-67.03%
-91.50 %+118.11%
-41.95 %+228.08%
-12.79 %-51.01%
-26.10 %+8,444.73%
-0.31 %-29.39%
-0.43 %+152.83%
-0.17 %+126.33%
-0.08 %-84.77%
-0.50 %+32.27%
-0.38 %-23.34%
-0.49 %+291.69%
-0.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Gene One Life Science Stock analysis

What does Gene One Life Science do? GeneOne Life Science, Inc. generates revenue through its biomedical contract manufacturing organization (CMO) services, producing DNA vaccines for disease prevention and treatment. The company also sells wicks under the brand INTERON for use in dress shirts, suits, and caps, and provides biopharmaceutical services including research, development, and manufacturing of plasmid DNA and DNA vaccines. Its leasing business involves nonresidential buildings. The primary buyers for the biomedical CMO services are likely pharmaceutical companies seeking contract manufacturing for DNA vaccines. INTERON wicks are purchased by apparel manufacturers producing dress shirts, suits, and caps. The leasing segment targets commercial property tenants requiring nonresidential space. The company serves the biomedical, textile, and real estate sectors through these distinct business segments. Gene One Life Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Gene One Life Science stock

EBIT Margin (Operating Margin) of Gene One Life Science is -195.55 % in 2025.

EBIT Margin (Operating Margin) of Gene One Life Science changed from -130.45 % to -195.55 %, representing a 49.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Gene One Life Science since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Gene One Life Science with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Gene One Life Science

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Gene One Life Science